GT Biopharma Inc (GTBP) — Cash Flow-to-Debt Ratio
GT Biopharma Inc (GTBP) has a Cash Flow-to-Debt Ratio of -1.02x as of March 2026, meaning its operating cash flow of $-2.47 Million could theoretically repay -1% of its total liabilities ($2.42 Million) in one year. Check total reinvestment intensity of GT Biopharma Inc to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GT Biopharma Inc Cash Flow-to-Debt Ratio (1985–2025)
Historical debt coverage capacity for GT Biopharma Inc across 41 annual periods. Also explore GT Biopharma Inc total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for GT Biopharma Inc (1985–2025)
Year-by-year debt coverage analysis for GT Biopharma Inc. For market capitalisation and broader financial context, see GTBP market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.57x | $-12.91 Million | $2.32 Million | ▼ -154.7% |
| 2024 | -2.19x | $-12.90 Million | $5.90 Million | ▼ -63.8% |
| 2023 | -1.33x | $-8.85 Million | $6.63 Million | ▲ +56.1% |
| 2022 | -3.04x | $-15.22 Million | $5.00 Million | ▼ -100.0% |
| 2021 | -1.52x | $-15.61 Million | $10.26 Million | ▼ -635.1% |
| 2020 | -0.21x | $-7.26 Million | $35.09 Million | ▼ -11.4% |
| 2019 | -0.19x | $-3.66 Million | $19.71 Million | ▲ +75.6% |
| 2018 | -0.76x | $-10.68 Million | $14.03 Million | ▲ +62.5% |
| 2017 | -2.03x | $-5.43 Million | $2.68 Million | ▼ -1890.0% |
| 2016 | -0.10x | $-1.93 Million | $18.95 Million | ▼ -10.7% |
| 2015 | -0.09x | $-4.66 Million | $50.62 Million | ▼ -60.2% |
| 2014 | -0.06x | $-1.75 Million | $30.46 Million | ▲ +15.8% |
| 2013 | -0.07x | $-442.00K | $6.48 Million | ▲ +54.7% |
| 2012 | -0.15x | $-987.00K | $6.56 Million | ▲ +18.3% |
| 2011 | -0.18x | $-963.00K | $5.23 Million | ▲ +32.2% |
| 2010 | -0.27x | $-1.53 Million | $5.65 Million | ▼ -105.9% |
| 2009 | -0.13x | $-937.00K | $7.11 Million | ▼ -233.1% |
| 2008 | -0.04x | $-169.00K | $4.27 Million | ▲ +52.7% |
| 2007 | -0.08x | $-270.00K | $3.23 Million | ▲ +2.7% |
| 2006 | -0.09x | $-671.00K | $7.80 Million | ▲ +82.5% |
| 2005 | -0.49x | $-2.09 Million | $4.27 Million | ▼ -26.1% |
| 2004 | -0.39x | $-1.04 Million | $2.68 Million | ▼ -85.6% |
| 2003 | -0.21x | $-229.00K | $1.09 Million | ▲ +84.1% |
| 2002 | -1.31x | $-1.01 Million | $767.00K | ▼ -9.6% |
| 2001 | -1.20x | $-1.43 Million | $1.19 Million | ▲ +52.1% |
| 2000 | -2.50x | $-3.89 Million | $1.55 Million | ▼ -152.3% |
| 1999 | -0.99x | $-2.48 Million | $2.50 Million | ▲ +23.6% |
| 1998 | -1.30x | $-5.20 Million | $4.00 Million | ▼ -57.1% |
| 1997 | -0.83x | $-4.80 Million | $5.80 Million | ▲ +32.6% |
| 1996 | -1.23x | $-4.30 Million | $3.50 Million | ▼ -29.8% |
| 1995 | -0.95x | $-5.30 Million | $5.60 Million | ▼ -1164.7% |
| 1994 | 0.09x | $400.00K | $4.50 Million | ▲ +101.7% |
| 1993 | -5.33x | $-1.60 Million | $300.00K | ▼ -540.0% |
| 1992 | -0.83x | $-500.00K | $600.00K | ▲ +16.7% |
| 1991 | -1.00x | $-200.00K | $200.00K | ▼ -122.2% |
| 1990 | 4.50x | $900.00K | $200.00K | ▲ +221.4% |
| 1989 | 1.40x | $700.00K | $500.00K | ▲ +320.0% |
| 1988 | 0.33x | $100.00K | $300.00K | ▲ +33.3% |
| 1987 | 0.25x | $50.00K | $200.00K | ▲ +131.3% |
| 1986 | -0.80x | $-400.00K | $500.00K | ▲ +73.3% |
| 1985 | -3.00x | $-300.00K | $100.00K | — |